Veranova invests $50 mn+ in ADC bioconjugation at Devens
Veranova, a global leader in the development and manufacturing of specialist and complex active pharmaceutical ingredients (APIs) for the pharmaceutical and biotech sectors, today announced a strategic investment to establish state-of-the-art bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus.
Veranova is investing over $50 million to add bioconjugation development and cGMP manufacturing at its Devens, MA site, creating up to 70 jobs. The expansion, set for June 2026, will support ADCs and other bioconjugates, addressing rising demand for US-based biomanufacturing. It builds on Devens' expertise in complex synthesis and linker-payload production.
This expansion will enable Veranova to provide a more comprehensive suite of services to partners developing antibody-drug conjugates (ADCs) and other bioconjugates, and builds on the Devens facility's extensive experience in the development and clinical and commercial manufacture of ADC linker-payloads. Combined with a previously announced expansion of high-potent synthesis capacity in Devens, this will represent a more than $50 million investment into the site's capabilities for ADCs and other bioconjugates and will create up to 70 new jobs. The new capacity is planned to come online in June 2026.
The investment also addresses increasing demand for strong U.S.-based biomanufacturing capabilities and will help U.S.-based customers secure domestic supply chains for critical drug substances.
The bioconjugation expansion will include new process and analytical development laboratories, grade C cleanroom space, development and cGMP equipment and instrumentation, and supporting infrastructure. These capabilities will support up to kilogram-scale manufacturing of potent and non-potent bioconjugates.
'We continue to see ADCs and other conjugated molecules as a key growth area as our customers look to develop more targeted therapies,' said Mike Riley, CEO of Veranova. 'This investment will build on our core capabilities in complex chemistry, analytics and linker-payload synthesis, and leverage our strategically located cGMP infrastructure to provide a differentiated solution to our customers.'
The Devens site is a key location in Veranova's global manufacturing network, situated in close proximity to the Boston-Cambridge biotechnology hub. The site has over 15 years of experience in the development and manufacture of linker-payloads and other complex synthetic molecules supported by expertise in complex synthesis, analytical development and testing, high potent handling, crystallization development, and chromatography purification. Veranova Devens is an FDA-approved facility with capabilities spanning early process and analytical development, scale-up, and clinical and commercial manufacturing under one roof. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged.
Fibre2Fashion News Desk (HU)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
26 minutes ago
- Time of India
Osaka Gas India powers ahead with clean energy vision
Tokyo: Japanese energy giant Osaka Gas, established in 1897, is making significant strides in India's energy sector. With a legacy of expertise in gas production, supply, and pipeline infrastructure, the company also maintains a strong presence in electricity generation. Following successful expansions across Asia, the United States, and Australia, Osaka Gas launched its Indian subsidiary, Osaka Gas India , in 2021. Now, four years later, the company is charting an ambitious course for clean and sustainable energy in the country. In an exclusive interview, Takeshi Shinohara, Managing Director of Osaka Gas India, reflected on the company's journey and expanding role in the Indian energy landscape. "In just four years, Osaka Gas India's operational area has expanded to cover 10 per cent of India's land--roughly equivalent to the size of Japan," said Shinohara. In India, Osaka Gas is actively engaged in city gas supply and pipeline construction, working in partnership with Chennai-based firm Think Gas. This collaboration has enabled rapid development of urban gas infrastructure and ensured efficient energy distribution. The company's long-term vision for India rests on three foundational pillars. The first is its traditional strength in city gas operations. The second is a growing focus on renewable energy . In partnership with Indian clean energy leader CleanMax, Osaka Gas India is generating electricity through solar and wind power, serving industrial clients that demand environmentally sustainable energy. "Our success so far has been made possible through strong partnerships with trusted Indian companies," Shinohara noted. Takeshi Shinohara emphasizes the third pillar of Indian business: new energy in the form of e-methane . "City gas emits CO2, but Osaka Gas India combines it with hydrogen derived from renewable sources to produce e-methane -- a circulative model of clean energy production," said Shinohara Shinohara emphasized that India's economic momentum and social transformation are fueling demand for smarter, greener energy options. "India's rising economic power and dynamic society will drive increasing demand for cleaner and more efficient energy solutions in the coming years," he said. Unlike passive financial investors, Osaka Gas operates with a "hands-on" philosophy, committed to transferring technical knowledge and building long-term capabilities within India. "Real Scene, Real Material, Reality," Shinohara stated, describing the company's core principles. "This reflects our deep commitment to operational excellence and grounded experience." Looking ahead, Osaka Gas sees India as an integral part of its global future. "By 2030, India will become a major pillar of Osaka Gas's global business," he predicted. Yet, Shinohara also highlighted the stark developmental contrasts between India's urban centers and rural heartlands, particularly in agricultural regions. "Osaka Gas India aims for real symbiosis with Indian society by combining our global experience with local understanding," he concluded. As India undergoes a profound transformation in its energy landscape, Osaka Gas India's integrated approach--grounded in innovation, collaboration, and sustainability--could play a pivotal role in shaping the country's clean energy future.
Indian Express
30 minutes ago
- Indian Express
Gold in colour, costs $499: Five things to know about Trump's new ‘Made in America' phone
The Trump Organisation, led by Donald Trump Jr. and Eric Trump, has launched 'Trump Mobile,' a new smartphone and wireless service. This venture aims to provide 'true value' to customers, particularly those underserved in the telecom industry. They claim their service will offer high-quality products and customer support, with a focus on conservative consumers. The Trump-branded smartphone will sell for $499 (around ₹41,400). Images show a gold-coloured device, and the phone is currently available for pre-order on Trump Mobile's official website with a $100 (₹8,300) deposit. The Trump family has said the phone will be made in the United States. But the BBC reported that industry experts have cast doubt on whether this is possible. Professor Tinglong Dai from Johns Hopkins University told the BBC, 'They don't even have a working prototype. It's extremely unlikely.' Another analyst, Leo Gebbie from CCS Insight, said, 'The US simply does not have the high-tech supply chain needed to build smartphones from scratch.' Gebbie added that the most likely scenario is that parts will be imported, and the phone may be assembled in the US. Trump Mobile will also offer a mobile phone plan that costs $47.45 per month (about ₹3,940) offering unlimited service, free international calls, and US-based support. The BBC reports that the announcement did not name the partner company running the service or explain the phone's technical specifications. Some critics have raised concerns about President Trump's personal financial benefit while in office. Meghan Faulkner, from the group Citizens for Responsibility and Ethics in Washington, told the BBC, 'It's unbelievable that the Trump family has created yet another way for President Trump to personally profit while in office.' The group also questioned whether the service might attract customers hoping to influence the president. So far, the Trump Organisation has not explained how or where the phone will be produced. On a podcast, Eric Trump said that eventually, all phones 'can be built in the United States', suggesting the first batch might not be entirely US-made. The company also hasn't revealed which firm will operate the mobile service or whether it will use existing mobile networks, like Verizon, AT&T, or T-Mobile. In its announcement, the Trump Organisation said, 'Hard-working Americans deserve a wireless service that's affordable, reflects their values, and delivers reliable quality they can count on.'
Mint
38 minutes ago
- Mint
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why
US-based multinational pharmaceutical giant Eli Lilly & Co., on Tuesday, 17 June 2025, announced its plans to acquire gene-editing biotech firm Verve Therapeutics Inc. for $1.3 billion as the big pharma company eyes expansion in experimental medicine for long-term growth, reported the news agency Bloomberg. According to the agency report, Eli Lilly & Co. will pay up to $13.50 per share for the acquisition deal. The breakdown of the deal will be that Eli Lilly & Co. will pay $10.50 per share in cash as well as a non-tradeable contingent value right that entitles the holder to receive as much as $3 extra per share. The transaction is expected to close in the third quarter of the current year, reported the news agency, citing the company. Verve Therapeutics shares skyrocketed 75.12% to $10.99 at the US stock market open at 9:38 a.m. (EDT), compared to $6.27 at the previous market close. However, pharma major Eli Lilly & Co. shares are trading 1.45% lower on Wall Street at $795.84 as of 9:40 a.m. (EDT), compared to $807.58 at the previous stock market close. The US big pharma company Eli Lilly & Co.'s revenues are centred around its iconic weight-loss drug, Zepbound, as the company prepares for the medicine's patent to expire. The news agency reported that the company has been able to target experimental medicines that are still far from the market. In this area, price tags are usually smaller than for therapies that have already undergone multiple patient trials. The long-term return on such early-stage deals can be far larger. In January 2025, Eli Lilly & Co. agreed to pay up to $2.5 billion for a cancer medicine which was being tested by Scorpion Therapeutics Inc., as per the agency report. Further in May, the company announced a plan to buy SiteOne Therapeutics Inc., a biotech firm developing pain medicines, for nearly $1 billion. Eli Lilly & Co. was reportedly in collaboration with Verve Therapeutics on its experimental gene-editing program for reducing lipoprotein, which is a risk factor for plaque buildup in human arteries. This acquisition deal will give Eli Lilly & Co. full control of the program, as the company shows confidence in its gene editing drug, which is a cutting-edge technology in the market, according to the report. However, this technology has struggled to attract investors recently, in part because it's expensive to make and aimed at providing one-time cures for rare diseases that may not be lucrative. Verve is a rare example of a gene editing company targeting a disease that affects a large population and offering better commercial prospects. Its approach, which uses tiny balls of fat to deliver the treatment, is less expensive to make than other gene therapies. Ruth Gimeno, the Vice President for diabetes and metabolic research and development at Eli Lilly & Co., told the news agency that the experimental therapy could be the first to edit genes inside a living body that's targeted to a broad population of patients.
